Drugs / recombinant fowlpox GM-CSF vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00091039 | Aug 2004 → Feb 2006 | lung cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant fowlpox GM-CSF vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00091039 ↗ |
| Known as | rF-GM-CSF | “Patients also receive recombinant fowlpox GM-CSF (rF-GM-CSF) vaccine SC with each vaccination.” NCT00091039 ↗ |
| Modality | Vaccine | “recombinant fowlpox GM-CSF (rF-GM-CSF) vaccine” NCT00091039 ↗ |
| Route | Subcutaneous | “Patients also receive recombinant fowlpox GM-CSF (rF-GM-CSF) vaccine SC with each vaccination.” NCT00091039 ↗ |